Autologous blood stem cell transplantation for Hodgkin and non-Hodgkin lymphoma: Complications and outcome.

Simple item page
dc.contributor.authorKumar, Lalit
dc.contributor.authorGanessan, Prasanth
dc.contributor.authorGhosh, Indraneel
dc.contributor.authorPanda, Deepanjan
dc.contributor.authorGogia, Ajay
dc.contributor.authorMandhania, Sushil
dc.date.accessioned2012-06-25T05:57:12Z
dc.date.available2012-06-25T05:57:12Z
dc.date.issued2010-11
dc.description.abstractBackground. We analysed data on patients of Hodgkin and non-Hodgkin lymphoma treated with high dose chemotherapy followed by autologous stem cell transplantation to determine the toxicity, pattern of infections and long term outcome. Methods. There were 34 male and 10 female patients (median age 35 years, range 15–67 years). Before transplantation, 31 patients (70.5%) had chemosensitive disease and 13 (29.5%) had chemoresistant disease. Granulocyte-colony stimulating factor mobilized peripheral blood stem cells were used as the source of stem cells. The patients received high dose chemotherapy using CBV (cyclophosphamide, BCNU and VP- 16 [etoposide] n=38), BEAM (BCNU, etoposide, cytosine arabinoside and melphalan, n=3), cytosine arabinoside, etoposide and melphalan (n=2) and melphalan alone (n=1). Prophylaxis with antifungal drugs (fluconazole/itraconazole) and acyclovir was used. Results. Following transplant, 32 patients (72.7%) responded; complete response was achieved in 25 patients (56.8%) and partial response in 7 (15.9%). The rate of complete response was higher for patients with pre-transplant chemosensitive disease (23/31 [74.2%] v. 2/13 [15.4%], p<0.001). Gastrointestinal toxicity, and renal and liver dysfunctions were major non-haematological toxicities; 3 patients (7%) died of regimen-related toxicity. Infections (predominantly Gram-negative) accounted for 2 deaths (4.5%) seen before day 30. At a median follow up of 79 months (range 14–168 months), median overall and event-free survival were 78 months and 28 months, respectively. Estimated mean (SE) overall and event-free survival at 60 months were 54.34% (0.07) and 34.3% (9.88), respectively. Conclusion. Patients with pre-transplant chemosensitive disease and those who achieved complete response following transplant had a significantly better chance of survival.en_US
dc.identifier.citationKumar Lalit, Ganessan Prasanth, Ghosh Indraneel, Panda Deepanjan, Gogia Ajay, Mandhania Sushil. Autologous blood stem cell transplantation for Hodgkin and non-Hodgkin lymphoma: Complications and outcome. National Medical Journal of India. 2010 Nov-Dec; 23(6): 330-335.en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/139153
dc.language.isoenen_US
dc.source.urihttps://www.nmji.in/archives/Volume-23/Issue-6/Original-Articles-II.pdfen_US
dc.subject.meshAdolescent
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols --therapeutic use
dc.subject.meshChi-Square Distribution
dc.subject.meshFemale
dc.subject.meshHematopoietic Stem Cell Transplantation --adverse effects
dc.subject.meshHodgkin Disease --drug therapy
dc.subject.meshHodgkin Disease --therapy
dc.subject.meshHumans
dc.subject.meshLymphoma, Non-Hodgkin --drug therapy
dc.subject.meshLymphoma, Non-Hodgkin --therapy
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshPrognosis
dc.subject.meshSurvival Rate
dc.subject.meshTransplantation Conditioning --methods
dc.subject.meshTransplantation, Autologous
dc.subject.meshTreatment Outcome
dc.titleAutologous blood stem cell transplantation for Hodgkin and non-Hodgkin lymphoma: Complications and outcome.en_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
nmji2010v23n6p330.pdf
Size:
165.88 KB
Format:
Adobe Portable Document Format
Description:
Journal article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
National Medical Journal of India